Bladder-preferential M3 muscarinic antagonist — designed for higher detrusor selectivity vs salivary gland. Active 5-OH metabolite via CYP2D6. Slightly cleaner anticholinergic profile than oxybutynin, but still meaningful Beers-list concerns.
Half-Life & Elimination Curve (PO: 2h)
Plasma (PO)t½ Decay (2h)Effect Site (ke0)
0×t½0h100%(3.72 µg/L)
1×t½2h50%(1.86 µg/L)
2×t½4h25%(0.93 µg/L)
3×t½6h12.5%(0.465 µg/L)
4×t½8h6.3%(0.233 µg/L)
5×t½10h3.1%(0.116 µg/L)
Elimination t½2h (PO)
Rate Constant (ke)0.347 h⁻¹
Time to Peak (Tmax)1.39h
Est. Peak (Cmax)3.72 µg/L
Clearance (CL)39.2 L/h
97% Washout (5×t½)10h
Dosing Guidelines
Oral (PO): Typical 4 mg (Range: 1–4 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 17% · Volume of Distribution (Vd): 113 L · Absorption (ka): 1.3 h⁻¹ (t½ka ≈ 32m) [PMID 9630826]